| 期刊全稱(chēng) | Anthracycline Antibiotics in Cancer Therapy | | 期刊簡(jiǎn)稱(chēng) | Proceedings of the I | | 影響因子2023 | Franco M. Muggia,Charles W. Young,Stephen K. Carte | | 視頻video | http://file.papertrans.cn/159/158255/158255.mp4 | | 學(xué)科分類(lèi) | Developments in Oncology | | 圖書(shū)封面 |  | | 影響因子 | F. M. MUGGIA When faced with the inadequacies of current cancer treatment, we prefer to look at what the future may hold. Quite often, we take for granted the past, preferring research into totally new areas. However, the persistent development of fertile soil may yield surprising rewards for those who choose to build on the knowledge of the past--hence, this symposium on anthracycline antibiotics. Although the anthracycline antibiotics represent much of the present and future of cancer treatment, their actual use c stretches back barely two decades to the pioneering efforts of Aurelio Di Marco, who characterized the antitumor properties of daunomycin and adriamycin. * The clinical application of these two compounds heralded a decade of excitement among oncologists dealing with pediatric tumors, breast cancer, leukemias, and lymphomas, and opened new hope for patients afflicted with sar- comas and a variety of other tumors that had been deemed - sistant to chemotherapy. These successes were tempered with the realization that the antitumor effect of anthracyclines could be achieved at times only at the very high price of risking cardiac decompensation and, almost invariably, with th | | Pindex | Conference proceedings 1982 |
The information of publication is updating
|
|
|Archiver|手機(jī)版|小黑屋|
派博傳思國(guó)際
( 京公網(wǎng)安備110108008328)
GMT+8, 2026-1-21 20:28
發(fā)表于 2025-3-21 17:03:51
